Publications (332) MARIA ISABEL LUCENA GONZALEZ publications View referenced research data.

filter_list

2025

  1. Drug-induced Liver Injury in Latin America: 10-year Experience of the Latin American DILI (LATINDILI) Network

    Clinical Gastroenterology and Hepatology, Vol. 23, Núm. 1, pp. 89-102

  2. Epigenetic modifications in drug-induced liver injury: A systematic review

    British Journal of Clinical Pharmacology

  3. Epigenetic modifications in drug-induced liver injury: A systematic review

    British journal of clinical pharmacology, Vol. 91, Núm. 6, pp. 1660-1674

  4. Genetic Variants of GBP4: Reduced Risks for Drug-Induced Acute Liver Failure in Non-Finnish European Population

    Liver International, Vol. 45, Núm. 2

  5. Intestinal permeability and immune-inflammatory markers in patients with idiosyncratic drug-induced liver injury, drug-induced steatosis and metabolic dysfunction–associated steatotic liver disease (MASLD)

    British Journal of Pharmacology

  6. Methods for causality assessment of idiosyncratic drug-induced liver injury

    Liver International, Vol. 45, Núm. 3

  7. Reply to: Correspondence on ‘Control compounds for preclinical drug-induced liver injury assessment: Consensus-driven systematic review by the ProEuroDILI network’

    Journal of Hepatology

  8. Short communication: miRNA122 interrogation via PCR-Free method to track liver recovery

    PLoS ONE, Vol. 20, Núm. 5 May

  9. Stanozolol-induced Liver Injury: A Distinctive Cholestatic Clinical and Biochemical Phenotype at Presentation

    Journal of Clinical and Experimental Hepatology, Vol. 15, Núm. 3

  10. Unmet needs in autoimmune liver diseases

    Current Opinion in Immunology, Vol. 95

2024

  1. Anticancer drugs are the first cause of drug-induced liver injury in a reference hospital

    Liver International, Vol. 44, Núm. 2, pp. 286-292

  2. Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries

    Archives of Toxicology, Vol. 98, Núm. 1, pp. 303-325

  3. Co-20. Evaluación de la influencia de enfermedades subyacentes en el daño hepático inducido por fármacos

    Revista andaluza de patología digestiva, Vol. 47, Núm. 5, pp. 241-242

  4. Control compounds for preclinical drug-induced liver injury assessment: Consensus-driven systematic review by the ProEuroDILI network

    Journal of Hepatology, Vol. 81, Núm. 4, pp. 630-640

  5. Correction to: Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative (Drug Safety, (2024), 47, 4, (301-319), 10.1007/s40264-023-01390-5)

    Drug Safety

  6. Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative

    Drug Safety, Vol. 47, Núm. 4, pp. 301-319

  7. Drug-induced autoimmune-like hepatitis

    Clinical Liver Disease, Vol. 23, Núm. 1

  8. La Farmacología básica y clínica española: una perspectiva desde Pharmacological research

    Actualidad en farmacología y terapéutica, Vol. 22, Núm. 2, pp. 106-109

  9. Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry

    Hepatology (Baltimore, Md.), Vol. 79, Núm. 3, pp. 538-550

  10. Neddylation inhibition prevents acetaminophen-induced liver damage by enhancing the anabolic cardiolipin pathway

    Cell Reports Medicine, Vol. 5, Núm. 7